Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Michael J. Soileau, Jason Aldred(Inland Northwest Health Services), Kumar Budur(AbbVie (United States)), Nahome Fisseha(AbbVie (United States)), Victor SC Fung(The University of Sydney), Anna Jeong(AbbVie (United States)), Thomas Kimber(The University of Adelaide), Kevin J. Klos(Allergy Clinic of Tulsa), Irene Litvan(University of California San Diego), Daniel I. O’Neill(South Western Sydney Local Health District), Weining Robieson(AbbVie (United States)), Meredith Spindler(University of Pennsylvania), David G. Standaert(University of Alabama at Birmingham), Saritha Talapala(AbbVie (United States)), Eleni Okeanis Vaou(St. Elizabeth's Medical Center), Hui Zheng(AbbVie (United States)), Maurizio Facheris(AbbVie (United States)), Robert A. Hauser(University of South Florida)
The Lancet Neurology
November 16, 2022
Cited by 194

Abstract


Related Papers

No related papers found

Powered by citation graph analysis